Items tagged with Guidelines

CDC releases updated recommendations for treatment of latent TB infection (post)

The U.S. Centers for Disease Control and Prevention (CDC) has issued updated recommendations regarding the use of 3HP (once-weekly isoniazid-rifapentine for 12 weeks) for the treatment of latent tuberculosis (TB) infection. 

Analysis: Not all good news in new WHO MDR-TB recommendations (post)

In a move that could help save the hearing of thousands of people with TB, the World Health Organisation (WHO) is advising wider use of newer and repurposed drugs, bedaquiline and linezolid in place of injections that cause deafness. Rather perplexingly, the WHO is however also maintaining its recommendation for a shorter and cheaper, but much less impressive treatment regimen and advised that the new South African regimen should only be used under conditions of operational research.

Handbook on TB laboratory diagnostic methods in the European Union – updated 2018 (post)

The aim of this handbook is to provide network members and other laboratories involved in the diagnosis of tuberculosis, with an agreed list of key diagnostic methods and their protocols in various areas of TB diagnosis, ranging from microbiological diagnosis of active TB to the diagnosis of latent TB infection.

European Union Standards for Tuberculosis Care - 2017 update (post)

The European Centre for Disease Prevention and Control (ECDC) and the European Respiratory Society (ERS) have developed 21 patient-centred standards to guide clinicians and public health workers in their work to ensure optimal diagnosis, treatment and prevention of tuberculosis (TB) in Europe. In 2017, the European Union Standards for Tuberculosis Care (ESTC) were updated to incorporate the most recent technological developments and international recommendations for TB diagnosis, treatment and prevention.

Frequently Asked Questions on the WHO Rapid Communication: key changes to the treatment of multidrug- and rifampicin-resistant TB (post)

The World Health Organization (WHO) in collaboration with the Stop TB Partnership’s Global Drug Facility, the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United States Agency for International Development have developed a set of frequently asked questions (and answers) in response to inquiries on upcoming WHO policy recommendations.

The sleeping giant: the danger of neglecting latent TB infection (post)

The European Centre for Disease Prevention and Control (ECDC) has published comprehensive guidance on the management of latent tuberculosis infection (LTBI) targeted for European Union/European Economic Area (EU/EEA) countries.

Union launches field guide for the management of drug-resistant TB (post)

The Union launched a new technical resource on drug-resistant tuberculosis (DR-TB) management during a press conference on DR-TB at the 49th Union World Conference on Lung Health, in The Hague, The Netherlands today (October 25).

Nursing Guide for Managing Side Effects to Drug-resistant TB Treatment (post)

Nursing Guide for Managing Side Effects to Drug-resistant TB Treatment is a collaborative project between the Curry International Tuberculosis Center (CITC) and the International Council of Nurses (ICN). The guide was developed by nurses with experience in the clinical care and programmatic management of tuberculosis (TB) and drug-resistant tuberculosis (DR-TB) in both high- and low-resource settings.

Page 3 of 8 · Total posts: 0

←First 2 3 4 Last→